Back to search

FRIMEDBIO-Fri prosj.st. med.,helse,biol

International symposium on Personalized Cancer Care: From risk prediction, early diagnosis, progression, and therapy.

Awarded: NOK 0.25 mill.

International Symposium on Personalized Cancer Care; What have we achieved since 2012 in risk prediction, early diagnosis, progression, and therapy? Oslo, May18-20, 2016, Holmenkollen Park Hotel Conference Center Opening keynote on P4 and Cancer: Leroy Hood, Institute for Systems Biology, Seattle, USA Speakers: 30 min followed by 10 min discussions to interact with the audience Session I: Genetic Profiling of Patients, Prediction of Risk and therapy response Bruce Ponder, Cancer Research Institute, Cambridge, UK Paul Pharoah, Strangeways Research Laboratory, Cambridge, UK Session II: Molecular Profiling of Tumors and Metastases Elaine Mardis, The Genome Inst., Washington Univ., St. Louis, Missouri, USA Zoltan Szallasi, Technical University of Denmark Carlos Caldas, Cancer Research Inst. Cambridge UK. Nicholas Navin, MD Anderson Cancr Center, Houston USA Peter van Loo, Crick Center, London, UK Session III: Tumor-host Microenvironment Interaction and Metabolism Arnold Levine, Princeton University, USA Larry Norton, Memorial Sloan-Kettering Cancer Center, NY; USA. Mina Bissell, Lawrence Berkeley National Laboratory, CA, USA Morag Park, McGill University, Montreal, Canada Session IV: Targeted Therapy Gordon Mills, MD Anderson Cancer Center, Houston USA Rene Bernards, The Netherlands Cancer Institute, Netherlands Joe Gray, Knight Cancer Inst. Oregon Health & Science Univ., Oregon USA Alberto Bardelli, University of Torino, Italy Soldano Ferrone, Massachusetts General Hospital, Harvard, Boston, USA Session VI: Translation Olli Kallioniemi, FIMM, Helsinki, Finland Laura van't Veer, University of California, San Francisco, USA Per Eystein Lønning, Univ Bergen, Norway Anne-Lise Børresen-Dale, Oslo Univ Hopsital, Norway Session V: The impact of social and ethical issues on personalized medicine Serena Nik-Zainal, Sanger Center, Hinxton, Cambridge, UK David Livingstone, Dana-Farber Cancer Institute; Boston, USA

Funding scheme:

FRIMEDBIO-Fri prosj.st. med.,helse,biol